ESR1 and breast carcinoma: Ample evidence has shown that estrogen and anti-estrogen agents, such as tamoxifen and fulvestrant, can specifically bind to the ligand binding domain of estrogen receptor α (ERα) to modulate differential expression of downstream transcriptional targets of ERα in breast cancer cells.